STOCK TITAN
  1. Home
  2. News
  3. ISPC

iSpecimen Inc - ISPC STOCK NEWS

Welcome to our dedicated news page for iSpecimen (Ticker: ISPC), a resource for investors and traders seeking the latest updates and insights on iSpecimen.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect iSpecimen's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of iSpecimen's position in the market.

News
iSpecimen Reports Full Year 2023 Results
Rhea-AI Summary
iSpecimen Inc. (ISPC) reported financial and operating results for 2023, focusing on profitability, revenue growth, and operational efficiencies. The company achieved its strongest sales month in December 2023, with revenue of $1.7 million. Despite a decrease in specimen count, the average selling price per specimen increased by 7%. iSpecimen also saw a 39% increase in the conversion of quotes to purchase orders in Q4 2023. The company had over 230 unique supplier organizations and 600 unique customer organizations by the end of 2023. Financially, revenue for 2023 was $9.93 million, with a net loss of $11.10 million. Cash and cash equivalents were $5.01 million as of December 31, 2023. iSpecimen entered into an At the Market Offering Agreement to issue and sell shares of common stock up to $1.5 million for further capital investments or general corporate purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-21.76%
Tags
earnings
-
News
iSpecimen Reschedules Full Year 2023 Earnings Release and Conference Call
Rhea-AI Summary
iSpecimen Inc. (ISPC) reschedules its financial results announcement to March 13, 2024, after the market closes, and conference call to March 14, 2024, featuring CEO Tracy Curley.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.2%
Tags
earnings
-
News
iSpecimen to Report Full Year 2023 Financial Results on March 13, 2024
Rhea-AI Summary
iSpecimen Inc. (ISPC) will report its financial results for the full year ended December 31, 2023, before the market opens on March 13, 2024. A conference call and webcast featuring remarks by CEO Tracy Curley will follow at 8:30 a.m. Eastern Time.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.01%
Tags
conferences earnings
News
iSpecimen and TriMetis Life Sciences Announce Strategic Partnership to Help Transform Tissue-Based Research
Rhea-AI Summary
iSpecimen Inc. partners with TriMetis Life Sciences to enhance quality control and assurance through digital AI histopathology services. The partnership aims to revolutionize tissue assessment for preclinical research by utilizing AI-powered solutions to standardize and enhance tissue sample evaluation, focusing on solid tumor types. This initiative will integrate technology solutions from TriMetis into iSpecimen's platform, providing researchers and suppliers access to critical data and AI-enhanced information. The partnership seeks to streamline procurement processes, increase accuracy, and reduce delays, ultimately cutting costs and delivering better outcomes for patients worldwide.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.04%
Tags
partnership
-
News
iSpecimen to Participate in Maxim Group Healthcare IT Virtual Conference, January 24 & 25, 2024
Rhea-AI Summary
iSpecimen Inc. (ISPC) will participate in the Maxim Group Virtual Healthcare IT Conference on January 25, 2024. Tracy Curley, CEO, will present at 10:00 a.m. ET. The company connects scientists with healthcare specimen providers for medical research.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.98%
Tags
conferences
-
News
iSpecimen Strengthens Global Oncology Biospecimen Offering
Rhea-AI Summary
iSpecimen Inc. (ISPC) expands its provider network to offer researchers increased access to highly-sought-after biospecimens for oncology research, adding new suppliers, expanding existing relationships, and introducing new offerings. The expansion includes access to specimens from cancer patients in different treatment stages, with specific biomarkers and mutations, across various tissue types and biofluid formats. The company also supports liquid biopsy research and offers custom collections with increased delivery options. iSpecimen continues to utilize next generation sequencing as part of the recent cancer sequencing procurement program.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.78%
Tags
none
News
iSpecimen Reports Third Quarter 2023 Financial and Operating Results
Rhea-AI Summary
iSpecimen Inc. (Nasdaq: ISPC) reported a sequential quarterly revenue growth of 75% driven by enhanced operational efficiencies and new business initiatives. Revenue for Q3 2023 was $2.8 million, a 75% increase from Q2 2023. The company also saw a 122% increase in the conversion of quotes to purchase orders. Unique supplier organizations under agreement increased to 234, and unique customer organizations increased to 603. iSpecimen Marketplace had 7,326 registered users, a 15% increase from last year.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.63%
Tags
earnings
-
News
iSpecimen Expands Proprietary Provider Network to Help Advance Infectious Disease Research
Rhea-AI Summary
iSpecimen Inc. has added new infectious disease specimen providers to its global supply network, expanding access to essential human tissue and biofluids for infectious disease research. The collaboration will provide researchers with access to clinically collected samples, banked tissues, and custom collections of biospecimens. iSpecimen's CEO, Tracy Curley, stated that the company's network and custom project capabilities will support diagnostic test and treatment development, leading to improved patient outcomes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.09%
Tags
none
-
News
iSpecimen Preannounces Third Quarter 2023 Revenue Increase of 60-70% Sequentially
Rhea-AI Summary
iSpecimen Inc. announces preliminary financial results for Q3 2023, expecting revenue between $2.6 to $2.8 million, a 60-70% increase from Q2 2023. The launch of the next-day quote program has driven higher financial performance, with a 122% conversion increase from quotes to purchase orders.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.58%
Tags
earnings
News
iSpecimen Launches Next-Day Quote Service for Medical Researchers and Biospecimen Providers
Rhea-AI Summary
iSpecimen Inc. introduces next-day quote service to accelerate biospecimen transactions, delivering accurate pricing within 24 hours of request.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Stock ISPC logo
iSpecimen Inc

Nasdaq:ISPC

ISPC Rankings

N/A Ranked by Market Cap
N/A Ranked by Stock Gains
N/A Ranked by Dividends

ISPC Stock Data

2.06M
6.90M
33.77%
4.31%
5.06%
Research and Development in the Physical, Engineering, and Life Sciences (except Biotechnology)
Professional, Scientific, and Technical Services
Link
United States
Lexington

About ISPC

headquartered in lexington, ma, ispecimen is the marketplace for human biospecimens, providing researchers with the specimens they need from the patients they want. the privately held company has developed the ispecimen marketplace, an online platform connecting healthcare organizations that have access to patients and specimens with the scientists who need them. proprietary, cloud-based technology enables researchers to intuitively search for specimens and patients across a federated partner network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. researchers easily and compliantly gain access to specimens to drive scientific discovery. partner sites gain an opportunity to contribute to biomedical discovery as well as their bottom line. and ultimately, healthcare advances for all.